Albert Bourla bought $1.0M of Pfizer (PFE)
Executed Aug 12, disclosed Aug 12, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 12), the stock returned +4.8% (delay-adjusted); from the execution session (Aug 12), +4.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Albert Bourla (Chairman & CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Pfizer Inc. (PFE). Across 1 priced purchase filing, the average 21-session return was +4.8% from execution and +4.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of PFE (38,000 sh × $26.34, as filed), executed Aug 12.
Healthcare · Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→